GI
ANIK icon

GAMMA Investing’s Anika Therapeutics ANIK Stock Holding History

GAMMA Investing’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.68K Buy
320
+31
+11% +$459 ﹤0.01% 3494
2026
Q1 		$4.19K Buy
+289
New +$3.35K ﹤0.01% 3426
2025
Q2 		– Sell
-426
Closed -$6.4K – 3779
2025
Q1 		$6.4K Buy
426
+293
+220% +$4.87K ﹤0.01% 2970
2024
Q4 		$2.19K Sell
133
-101
-43% -$1.99K ﹤0.01% 3195
2024
Q3 		$5.78K Buy
234
+114
+95% +$2.96K ﹤0.01% 2695
2024
Q2 		$3.04K Sell
120
-58
-33% -$1.5K ﹤0.01% 2748
2024
Q1 		$4.52K Hold
178
– – ﹤0.01% 2452
2023
Q4 		$4.19K Buy
+178
New +$3.68K ﹤0.01% 2318

Other funds holding ANIK

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
CWP
Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

GAMMA Investing's ANIK Position: Q2 2026 in Review

GAMMA Investing increased its Anika Therapeutics (ANIK) stake by 11% in Q2 2026, buying an estimated $459 and bringing the position to 320 shares worth $4.68K. The position accounts for ﹤0.01% of the portfolio, ranked #3494.

GAMMA Investing first reported a position in ANIK in Q4 2023 and has held it in 8 quarters since. The position peaked at $6.4K in Q1 2025. 8 funds tracked by Wall St. Rank hold ANIK as of Q2 2026.

  • GAMMA Investing held 320 shares of Anika Therapeutics worth $4.68K as of Q2 2026.
  • GAMMA Investing bought 31 Anika Therapeutics shares in Q2 2026, an estimated $459.
  • Anika Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #3494 holding.
  • GAMMA Investing first reported a position in Anika Therapeutics in Q4 2023 and has held it in 8 quarters since.
  • GAMMA Investing's Anika Therapeutics position peaked at $6.4K in Q1 2025.
  • 8 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.